Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

BD, Babson to enable blood collection in retail settings

April 2020—Becton Dickinson and Babson Diagnostics, a diagnostic blood testing company, announced a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies. BD’s capillary specimen collection devices, in development, are designed to enable the collection of laboratory-quality specimens without the need to access a vein and are for use in health care settings without a trained phlebotomist, such as retail pharmacies, physician offices, urgent care centers, and skilled nursing facilities. Babson’s offerings include proprietary automated sample handling and analytical technologies, which are also in development.

Leica Biosystems digital pathology scanner

April 2020—Leica Biosystems launched the Aperio GT 450, its next-generation digital pathology scanner. The research-use-only Aperio GT 450 offers continuous rack loading with priority scanning and takes 32 seconds to scan a 15 mm × 15 mm tissue area on a pathology slide at 40× magnification with a throughput of 81 slides per hour. The system’s slide racks are compatible with other Leica Biosystems products.

FDA authorizes marketing of Fragile X syndrome dx

April 2020—The FDA authorized the marketing of AmplideX Fragile X Dx and Carrier Screen Kit (Asuragen). It is the first test, according to the FDA, to detect Fragile X syndrome, the most common known cause of inherited developmental delay and intellectual disability. Additionally, this test is intended for use in adults who may be carriers of genetic alterations in the FMR1 gene.

FDA approves neratinib for metastatic HER2+ breast cancer

April 2020—The FDA approved neratinib (Nerlynx, Puma Biotechnology) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the metastatic setting.

New England Tissue Issue joins ProPath

April 2020—ProPath announced that New England Tissue Issue, a dermatopathology practice in Fall River, Mass., has joined the ProPath family of companies. The partnership will allow 8 million patients from NETI’s catchment area in-network access to ProPath’s esoteric testing.

Thermo Fisher digital dispensers

April 2020—Thermo Fisher Scientific launched the Thermo Scientific Multidrop Pico 1 and Pico 8 Digital Dispensers, designed to enable assay miniaturization, boost productivity, and improve accuracy of results. The systems dispense reagent volumes between 11 pL and 200 µL in any well and are suitable for a broad array of low-volume applications, including quantitative polymerase chain reactions, dose response curves, drug screening assays, serial dilutions, genotyping reactions, and enzyme-linked immunosorbent assays.

EC approves venetoclax + obinutuzumab for CLL

April 2020—Roche announced that the European Commission has approved Venclyxto (venetoclax) in combination with Gazyvaro (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia.

Quest selects Siemens Atellica for IA testing

April 2020—Siemens Healthineers announced it was selected by Quest Diagnostics to be Quest’s preferred supplier for immunoassay testing. As part of the multiyear agreement, Quest will deploy up to 120 Atellica Solution immunoassay analyzers in 19 esoteric and core laboratories in the United States.

FDA approves first drug for children with peanut allergy

April 2020—The U.S. Food and Drug Administration approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. Treatment with Palforzia (Aimmune Therapeutics) may be initiated in individuals ages four through 17 years with a confirmed diagnosis of peanut allergy and may be continued in individuals four years of age and older. Those who take Palforzia must continue to avoid peanuts in their diets.

MARKETPLACE

TRENDING